Skip to content

Mesa Laboratories

US · MLAB #3485 by market cap
127.93 -5.48 -4.11%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 12 in the most recent period (2026/Q3).
  • Total institutional ownership rose 5.1 percentage points.

Ownership vs. money flow

Aligned

Institutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
97.30% +5.09pp
Institutions
221 +12
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund69.51%
Hedge Fund17.85%
Public Company6.44%
Individual/Insider3.06%
Private Company2.06%
Government Pension Fund0.91%
Family Office/Trust0.31%
Insurance Company0.19%
Other1.04%

Top holders as of 2026-06-30

Long Path Partners, LP 8.49% · 477.13K sh
BlackRock 8.14% · 457.60K sh
Wasatch Advisors LP 6.89% · 387.13K sh
Victory Capital Management Inc. 4.92% · 276.57K sh
Vanguard Capital Management, LLC 4.20% · 236.21K sh
Boston Partners Global Investors, Inc. 4.74% · 265.15K sh
AQR Capital Management 3.60% · 202.10K sh
Geode Capital Management, LLC 2.95% · 165.74K sh
Ranger Investment Management, L.P. 3.11% · 173.99K sh
Dimensional Fund Advisors 2.92% · 163.91K sh
Diamond Hill Capital Management, LLC 2.78% · 155.77K sh
Raymond James Financial, Inc. 2.67% · 149.94K sh
Morgan Stanley 2.49% · 140.02K sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 25 buys · 14 sells

NameRoleStake
John Sullivan Chairperson 1.15%
John Sakys Vice President 0.67%
Brian Archbold Senior Vice President of Operations & Continuous Improvement 0.33%
Shiraz Ladiwala Lead Independent Director 0.22%
R. Tripeny Independent Director 0.16%
Jennifer Alltoft Independent Director 0.14%
Siddhartha Kadia Chief Executive Officer 0.13%
Shannon Hall Independent Director 0.12%
Mark Capone Independent Director 0.11%
Lyndsey Crennen Chief Accounting Officer 0.04%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-09 Sanket Shah -- Initial Statement of Beneficial 0 --
2026-10-12 John Sullivan Chairperson Other Disposition -1,200 --
2026-09-08 Shiraz Ladiwala Lead Independent Director Other Derivative Acquisition +2,510 --
2026-09-08 John Sullivan Chairperson Other Derivative Acquisition +1,774 --
2026-09-08 R. Tripeny Independent Director Other Derivative Acquisition +1,774 --
2026-09-08 Mark Capone Independent Director Other Derivative Acquisition +2,423 --
2026-09-08 Shannon Hall Independent Director Other Derivative Acquisition +1,774 --
2026-08-26 Gary Owens Former Chief Executive Officer Intent to Sell (Form 144) -20,358 $127.75
2026-08-20 Gary Owens Former Chief Executive Officer Intent to Sell (Form 144) -20,000 $122.50
2026-08-14 Shiraz Ladiwala Lead Independent Director Derivative Exercise and Retained +3,810 --
2026-08-14 John Sullivan Chairperson Derivative Exercise and Retained +2,784 --
2026-08-14 R. Tripeny Independent Director Derivative Exercise and Retained +2,784 --
2026-08-14 Mark Capone Independent Director Derivative Exercise and Retained +2,784 --
2026-08-14 Shannon Hall Independent Director Derivative Exercise and Retained +2,784 --
2026-08-14 Jennifer Alltoft Independent Director Derivative Exercise and Retained +2,784 --
2026-08-12 John Sullivan Chairperson Private Disposition -7,093 $112.80
2026-08-12 R. Tripeny Independent Director Open Market Acquisition +900 $113.69
2026-08-12 Siddhartha Kadia Chief Executive Officer Private Acquisition +7,093 $112.80
2026-06-21 John Sakys Vice President Automatic Disposition -2,827 $89.50
2026-06-21 Brian Archbold Senior Vice President of Operations & Continuous Improvement Open Market Disposition -2,516 $89.50

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Mesa Laboratories discussion 0 comments

Add a comment